Protein C News and Research

RSS

FDA approves Rybrevant for treating subset of non-small cell lung cancer

Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

21 May 2021

Study could lead to new antibiotics to fight bacterial infections

One member of a large protein family that is known to stop the spread of bacterial infections by prompting infected human cells to self-destruct appears to kill the infectious bacteria instead, a new study led by UT Southwestern scientists shows.

21 May 2021

University of Freiburg professor honored for groundbreaking results on the brain’s immune system

The blood-brain barrier is an impenetrable barrier between the circulating blood and the brain established before birth that prevents immune cells from entering the brain from the body's immune system. Thus, the brain has its own immune system with a key actor called microglia.

21 May 2021

Novel broad-spectrum antiviral compounds effective against Zika and SARS-CoV-2

A research team at the University of Alberta, Canada, led by Dr. Daniel Limonta, has described two novel molecules with broad antiviral properties that are effective against a range of virus types, including SARS-CoV-2.

21 May 2021

How do common mutations in SARS-CoV-2’s spike affect its binding affinity with host cell receptors?

Antibodies produced during a previous case of COVID-19 or vaccine-induced immunity are targeted towards S protein, where the neutralizing antibodies attach to the Spike RBD domain. Some of the variants have mutations in their RBD domain, causing resistance to the neutralizing antibodies. However, the effect of these mutations on the affinity and kinetics of the binding of Spike RBD to ACE2 is not clear. A new study has been published on the bioRxiv* preprint server, which deals with the study of affinity and kinetic analysis of the interface between Spike RBD and ACE2 at physiological temperatures.

21 May 2021

Pfizer-BioNTech vaccination not associated with platelet activation in new study

Among the devastating complications of severe or critical coronavirus disease 2019 (COVID-19), clot formation ranks high in the adverse impact it creates. An important question is whether SARS-CoV-2-spike-based vaccines also cause such coagulopathies. A new study, released as a preprint on the medRxiv* server, examines this risk for the first time.

21 May 2021

Can SARS-CoV-2 trigger amyloidosis?

A new study, released as a preprint on the bioRxiv* server, describes the results of an analysis of the role played by the virus in amyloid formation, with its subsequent effects on the health of various organs and of the whole organism.

21 May 2021

Scientists discover novel defensive response to SARS-CoV-2

Scientists from Hokkaido University have discovered a novel defensive response to SARS-CoV-2 that involves the viral pattern recognition receptor RIG-I. Upregulating expression of this protein could strengthen the immune response in COPD patients.

21 May 2021

Facets of SARS-CoV-2 infection and animal models

A new study in the journal Frontiers in Cell and Developmental Biology discusses the ribonucleic acid (RNA) genome of the virus, and the mechanisms by which it establishes infection within the host cell. The researchers also summarize the development of animal models of COVID-19, which will both help understand the clinical features of the illness, and indicate new approaches for the treatment of the infection.

21 May 2021

Biognosys Announces the Appointment of Kristina Beeler as Chief Business Officer

Biognosys announces the appointment of Kristina Beeler as Chief Business Operator

From Biognosys 21 May 2021

Metal complexes against coronavirus

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused more than 3.42 million deaths worldwide. Despite the fact that there are vaccines for SARS-CoV-2, the emergence of new variants and the lack of adequate treatments have encouraged the search for new ways to combat this disease more effectively.

21 May 2021

Canopy Biosciences develops spatial proteomics assay for COVID-19

Canopy Biosciences, a Bruker Company, today announced the successful development of a new assay for examining immune response to COVID-19.

From Bruker Nano Surfaces and Metrology 21 May 2021

Study shows distinctive mutation in rapidly emerging SARS-CoV-2 B.1.1.7 sublineage

In a new study currently available on the medRxiv* preprint server, US researchers report the detection of a specific sub-lineage of B.1.1.7 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant harboring a novel S:D178H mutation and elucidate its transmission and evolutionary patterns.

21 May 2021

SARS-CoV-2 spike mutation can independently predict viral evolution

A team of scientists from Portugal has recently estimated the rate of mutation in two circulating variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using experimental evolution methods. Their findings reveal that in a condition with no immune surveillance, SARS-CoV-2 can potentially undergo evolution during the first stages of infection. The study is currently available on the bioRxiv* preprint server.

21 May 2021

TIBI receives GFI grant to develop a unique, effective method of producing cultivated meat

The Terasaki Institute for Biomedical Innovation (TIBI) has been awarded a grant by The Good Food Institute (GFI) to develop a unique and effective method of producing cultivated meat, which is meat grown directly from the cell.

21 May 2021

Targeting mTOR pathway can improve the effectiveness of chemotherapies for pediatric brain cancer

Two experimental drug approaches that target vulnerabilities in cancer cell metabolism may extend survival and enhance the effectiveness of standard chemotherapies for a highly aggressive type of pediatric brain cancer.

21 May 2021

Pfizer-BioNTech and Sinovac vaccines boost SARS-CoV-2 neutralizing responses

Researchers in the United States and Chile have provided preliminary evidence that individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – mount a robust neutralizing antibody response against the virus that can be significantly boosted by two doses of Sinovac Biotech’s CoronaVac vaccine or one dose of Pfizer-BioNTech’s BNT162b2 vaccine.

21 May 2021

North America has 87% of all unique SARS-CoV-2 S protein variants in the NCBI database among six continents

Recently, a team of researchers from various countries analyzed the unique variants of S proteins across six continents, including Africa, Asia, Oceania, Europe, South America, and North America. They wanted to characterize the unique S protein variants embedded in SARS-CoV-2 genomes infecting millions of people globally.

20 May 2021

Researchers speculate the low prevalence of COVID-19 in Japan

Protective immune memory--through B cells, which make antibodies, and/or T cells, which in the case of CD8+ T cells can kill virus-infected cells--can be induced by identical but also by related viruses.

20 May 2021

Scientists discover key component to repair the molecular motor of human heart

A team of scientists from Loyola University Chicago's Stritch School of Medicine have discovered a critical component for renewing the heart's molecular motor, which breaks down in heart failure.

20 May 2021

Protein C News and Research

FDA approves Rybrevant for treating subset of non-small cell lung cancer

Study could lead to new antibiotics to fight bacterial infections

University of Freiburg professor honored for groundbreaking results on the brain’s immune system

Novel broad-spectrum antiviral compounds effective against Zika and SARS-CoV-2

How do common mutations in SARS-CoV-2’s spike affect its binding affinity with host cell receptors?

Pfizer-BioNTech vaccination not associated with platelet activation in new study

Can SARS-CoV-2 trigger amyloidosis?

Scientists discover novel defensive response to SARS-CoV-2

Facets of SARS-CoV-2 infection and animal models

Biognosys Announces the Appointment of Kristina Beeler as Chief Business Officer

Metal complexes against coronavirus

Canopy Biosciences develops spatial proteomics assay for COVID-19

Study shows distinctive mutation in rapidly emerging SARS-CoV-2 B.1.1.7 sublineage

SARS-CoV-2 spike mutation can independently predict viral evolution

TIBI receives GFI grant to develop a unique, effective method of producing cultivated meat

Targeting mTOR pathway can improve the effectiveness of chemotherapies for pediatric brain cancer

Pfizer-BioNTech and Sinovac vaccines boost SARS-CoV-2 neutralizing responses

North America has 87% of all unique SARS-CoV-2 S protein variants in the NCBI database among six continents

Researchers speculate the low prevalence of COVID-19 in Japan

Scientists discover key component to repair the molecular motor of human heart

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News